Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liraglutide + empagliflozin
- Development stage
- Phase 4
- Lead developer
- Novo Nordisk
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous, Oral
01
Overview
A combination therapy consisting of liraglutide, a GLP-1 receptor agonist, and empagliflozin, an SGLT-2 inhibitor. Liraglutide works by enhancing insulin secretion, reducing glucagon secretion, and slowing gastric emptying, while empagliflozin increases glucose excretion through the kidneys. This combination provides complementary mechanisms for glycemic control in type 2 diabetes management.
- Other names
- Empagliflozin and Liraglutide combinationLiraglutide and Empagliflozin combination
02
Targets
GLP1R (GLP-1R)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on liraglutide + empagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liraglutide + empagliflozin.